Survival prediction in glioblastoma: 10-year follow-up from the Dutch Neurosurgery Quality Registry
Authors:
Open Access
- 23 May 2025
- journal article
- case study
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 174 (3) , 753-764
Abstract
Purpose: Glioblastoma is the most common and treatment-resistant primary malignant brain tumor, with high morbidity and mortality despite standard treatment protocols. This study aims to evaluate survival and prognostic factors, and introduce two pragmatic prognostic models to inform individualized, patient-centered decision-making, using a large Dutch registry. Methods: We analyzed a prospective cohort of 7621 patients (2012–2022) in 12 Dutch centers via the Dutch Quality Registry Neurosurgery. Univariate analysis of prognostic factors, Kaplan–Meier survival curves, and funnel plots comparing center performance (30-day and 2-year mortality) were conducted. Two prognostic models using multivariate Cox regression were developed. Results: Glioblastoma incidence was 3.9/100.000 in The Netherlands. Overall, 30-day mortality was 5.1% and 2-year survival 17.8%. Overall median survival was 10.4 months, with 4.6 months after biopsy and 12.9 months post-resection. Poorer survival correlated with older age, higher ASA classification, lower Karnofsky Performance Status, biopsy over resection (HR 0.49, 95% CI 0.47–0.52), and postoperative complications (HR 1.57 95% CI 1.39–1.79). MGMT promotor methylation (HR 0.58, 95% CI 0.53–0.63) and adjuvant treatment were linked to lower mortality. Treatment variation and outcomes were within expected ranges; surgical volume did not affect survival. The prognostic models had C-indices of 0.704 (6-month) and 0.721 (2-year). Conclusion: Surgical resection and adjuvant therapy improved survival, but prognosis remained poor. Age, premorbid condition, treatment and molecular markers influenced survival. Center variations were within expected range, and higher surgical volume did not improve outcomes. The developed prognostic models could potentially inform clinicians, pending external validation.Keywords
This publication has 41 references indexed in Scilit:
- Survival in glioblastoma: a review on the impact of treatment modalitiesClinical and Translational Oncology, 2016
- Glioblastoma in England: 2007–2011European Journal of Cancer, 2015
- Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysisNeuro-Oncology, 2015
- ‘Just give me the best quality of life questionnaire’: the Karnofsky scale and the history of quality of life measurements in cancer trialsChronic Illness, 2012
- Patterns of Care and Survival in a Retrospective Analysis of 1059 Patients With Glioblastoma Multiforme Treated Between 2002 and 2007Neurosurgery, 2010
- Excluding venous thromboembolism using point of care D-dimer tests in outpatients: a diagnostic meta-analysisBMJ, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Funnel plots for comparing institutional performanceStatistics in Medicine, 2004